News >

Shorter Adjuvant Oxaliplatin-Based Therapy Less Effective in High-Risk Stage II CRC

Jessica Hergert
Published: Friday, Sep 06, 2019

Tim J. Iveson, MD, FRCP, a medical oncologist at University Hospital Southampton NHS Foundation Trust

Tim J. Iveson, MD, FRCP

Three months of adjuvant oxaliplatin-based therapy in patients with high-risk, stage II colorectal cancer (CRC) was found to be inferior to 6 months of treatment, according to results from a prospective pooled analysis of 4 randomized trials that were presented at the 2019 ASCO Annual Meeting.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x